Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428616 | 0.93 | TRPV1 (0.61) | TRPV1EGFRALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5431058 | 0.90 | TRPV1 (0.58) | TRPV1EGFRALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5431074 | 0.90 | TRPV1 (0.57) | TRPV1EGFRALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5438270 | 0.89 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL5432627 | 0.87 | TRPV1 (0.61) | TRPV1EGFRALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5432639 | 0.87 | TRPV1 (0.55) | TRPV1EGFRALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5433524 | 0.86 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL5439742 | 0.85 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL5436057 | 0.85 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL5447576 | 0.84 | TRPV1 (0.54) | TRPV1ALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | PIGS, GPR35, HRH4 | TRPV1 358/4885EGFR 399/4885ALDH1A1 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.